UK Biotech Closes €50M Series A for GPCR Drug Discovery

Published

February 17, 2020

UK Biotech Closes €50M Series A for GPCR Drug Discovery

Oxford-based OMass Therapeutics has extended its Series A round by €33M to fund the spectrometry-assisted development of drugs targeting G protein-coupled receptors…

MORERelated News
Is big pharma falling back in love with small molecules?
New approaches to small-molecule design allow difficult targets to be addressed, such as the G protein-coupled receptors (GPCR) on cell...
Women in Bio: OMass Taps Biogen Vet Nathalie Franchimont for Board of Directors
When U.K.-based OMass Therapeutics began the search for a new member for its board of directors, Chief Executive Officer Rosamond...
UK biotech OMass raises £27.5m for GPCR drug discovery
Oxford, UK-based OMass Therapeutics has extended its first-round financing to more than £41 million ($53 million), to help it fund...